Acceleron Pharma Inc (XLRN) Return on Equity ROE from the third quarter 2021 to third quarter 2020 and annually, average high and low, overall ranking from Sep 30 2021 to Sep 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Acceleron Pharma inc  (NASDAQ: XLRN)

Acceleron Pharma Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Acceleron Pharma Inc in the third quarter 2021?
Acceleron Pharma Inc recorded a cumulative net loss of $-255 million during 12 months ending in the third quarter 2021, resulting in a negative return on equity (ROE) of -32.39%.

Within the Biotechnology & Pharmaceuticals industry 53 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2021 from 0 to 3458.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Equity Change -19.77 % 80.98 % 95.94 % 90.25 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -255 -224 -179 -166 -132
Return On Equity (TTM) -32.39 % -26.91 % -23.95 % -25.68 % -24.26 %
XLRN's Total Ranking # 3458 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 718 763 811 855 895
Seq. Equity Change -5.88 % -5.89 % -5.18 % -4.47 % 112.31 %
Seq. Net Income Change - - - - -

Back to XLRN Management Effectiveness >> XLRN's 5 Years Annual ROE >> Compare XLRN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 54
Sector # 409
Overall # 3458

Return On Equity Statistics
High Average Low
1778.83 %
31.51 %
-48.57 %
(Mar 31 2014)   (Dec 31 2015)





XLRN Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016
Total Equity in Millions 855 449 292 365 226
Y / Y Equity Change 90.25 % 53.91 % -20.04 % 61.89 % 106.47 %
Net Income in Millions -166 -125 -119 -108 -57
Y / Y Net Income Change - - - - -
Return On Equity -19.42 % -27.78 % -40.7 % -29.7 % -25.27 %

Back to XLRN Management Effectiveness >> XLRN's 5 Years Annual ROE >> Compare XLRN ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
XLRN's' Return on Equity at Yahoo Finance
XLRN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for XLRN's Competitors
Subscribers only: Roe for Acceleron Pharma Inc's Suppliers
Subscribers only: Return On Equity for XLRN's Customers




Companies with similar Return On Equity at Sep 30 2021, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.